Biogen (BIIB) puts more active than calls into decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE

March 21, 2019 7:42 AM

Biogen (NASDAQ: BIIB) call put ratio 1 call to 1.6 puts with focus on March weekly 315 puts into the company and partner Eisai (ESALY) announcing the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE.

Categories

FDA Options Trader Talk

Next Articles